Home
Provention Bio

Provention Bio Market Share Analysis for February 2026

By Dr. Michael Greenberg, Vice President, Medical Head Vaccines, North America

Health > Biotechnology and Pharmaceuticals

Domainproventionbio.com

Year Founded2016

Employees51 - 200

Annual Revenue$10M - $15M

Provention Bio

Provention Bio (including company regionals)

proventionbio.com

See more website traffic and engagement information

Provention Bio Revenue up to February 2026 is 10M - 15M

revenue generated by Provention Bio top domains

Provention Bio top domains revenue over 3 years

Revenue for Provention Bio top domains

proventionbio.com10M - 15M

See more with Sales Intelligence

Total visits to Provention Bio's top domains

Understand Provention Bio market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Provention Bio's top domains

Analyze Provention Bio engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Provention Bio's top domains

See how Provention Bio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Provention Bio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Provention Bio

These are the website technologies, by industry, used by Provention Bio top domains

Conversion & Analytics (3)

Google Analytics

Advertising (2)

DoubleClick

Content Management System (2)

WordPress

Mobile (2)

Meta Viewport

More Technologies

9

See all

News & Signals from Provention Bio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsEacademy Sanofi acquires Provention Bio Inc. for $2.9B.The same day, Sanofi acquired Provention Bio for $2.9 billion to enhance its diabetes medicine portfolio.

NewsSanofi acquired Provention Bio Inc. for $2.9B on Mar 20th '23.Paris, France – April 10, 2023 – Sanofi announced today that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Sanofi's pending acquisition of Provention Bio, Inc.

NewsProvention Bio Inc. had issues with possible breaches of fiduciary duty and other violations of law on Mar 13th '23.MILWAUKEE, March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Provention Bio (Nasdaq: PRVB) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.